Invo Fertility, Inc. · NASDAQ:IVF
Invo Fertility — Investor Presentation (August 2026)
30 slides from Invo Fertility's investor presentation, Aug 28, 2026
Slide 1: Corporate Presentation August 2026
O)INVO fertility AUGUST 2026 CORPORATE PRESENTATION
Slide 2: Important Disclosures
ONVieriliry Naspaa: IMPORTANT DISCLOSURES FORWARD-LOOKING STATEMENTS ‘This presentation incudes forrardlooking statements within the meaning of Section 27A ofthe Securtes Act of 1893, as amended, and Secton 21€ ofthe Secures Exchange Act of 1894, as amended. Al statements made in this presentation h
Slide 3: Our Mission: What INVO Fertility Does
Owvo tertility NASDAQ: IVF OUR MISSION WHAT INVO FERTILITY DOES We are a healthcare fertility company focused on making advanced fertility care effective, accessible, and empowering for all, through a patient-centered approach that is powered by innovation, compassion and an exceptional team @ OWN A
Slide 4: INVO Fertility at a Glance
Owvo tertility NASDAQ: IVF INVO FERTILITY AT A GLANCE A FERTILITY SERVICES PLATFORM AT AN INFLECTION POINT 4 $7.5M $829K FERTILITY CLINICS TTM REVENUE TTM CLINIC-LEVEL ADJ. EBITDA Wisconsin - Georgia TIM ended June 20, 2026, $282k in 02 2028 ‘Alabama + indiana $3.7M $16.5M 2040 CASH AT JUNE 30, 2026
Slide 5: Company Evolution: Device Maker to Fertility Platform
Owvo tertility COMPANY EVOLUTION NASDAQ: FROM DEVICE MAKER TO FERTILITY PLATFORM IVF DEVICE COMPANY + Developed and commercialized INVOcell the first device to allow fertilization and early embryo development to take place in vivo + Sold and distributed INVOcellto third-party fertlity elinies + Reve
Slide 6: Why Now: An Inflection Point
Ovo NASDAQ: IVF WHY NOW AN INFLECTION POINT STRUCTURAL OPERATIONAL All Series C-2 preferred converted or retired and warrant liabilities eliminated; $7.1M of net proceeds received from warrant exercises in Hi 2026. @ Materially stronger balance sheet (Cash of $3.7M vs. $2.1M at year-end; total labil
Slide 7: Market and Consolidation: The Opportunity
Oiwvoteiity j= “Sy Men aNaspA @: IVF MARKET AND CONSOLIDATION THE OPPORTUNITY ee
Slide 8: Fertility Market
Owvo tertility FERTILITY MARKET NASDAQ: IVF U.S. IVF: SCALE, GROWTH AND STRUCTURAL DEMAND $5.9B 457 1in6 U.S. IVF MARKET SIZE REPORTING ART CLINICS PEOPLE AFFECTED 2025 market size, growing at an estimated 4.5% CAGR 435,426 ART cycles performed in 2022, roughly 810% CAGR ‘Share of people globally wh
Slide 9: The Consolidation Opportunity
Owvo tertility U.S. ART Cl ics by Ownel ‘Independent practices Private Academic / health system ce: INVO estimates based on market esearch, applied August 2026 NASDAQ: IVF THE CONSOLIDATION OPPORTUNITY A FRAGMENTED MARKET DESPITE ACTIVE CONSOLIDATION rship Type equity / venture-afiliated he 457 repo
Slide 10: Why Independent Clinics Choose INVO Fertility
ONVieriliry NASDAQ: IVF ADVANTAGES WHY INDEPENDENT CLINICS CHOOSE INVO FERTILITY ‘An owner-operator, not a financial sponsor INVO runs fertility clinics itself. Sellers partner with a team that understands clinic and lab operations and cycle economics — nota sponsor learning the business on their pr
Slide 11: Clinics, Model and Strategy
CLINICS, MODEL AND STRATEGY OUR PLATFORM
Slide 12: Fertility Centers: Four Operating Clinics
Owvo tertility FERTILITY CENTERS NASDAQ: IVF FOUR OPERATING CLINICS ACROSS FOUR STATES ; remy eis wisc@nsin 289 —- f ili bloom fertility INNOVATIVE ertllity ai INN@VATIVE LOCATION Middleton, Wi Atlanta, GA Birmingham, AL Indianapolis, IN PROCEDURES: IVF; IVC planned IVC; IVF planned IVF and IVC IVF
Slide 13: The Operating Model
Owvo tertility NASDAQ: IVF THE OPERATING MODEL LOCAL CLINICAL EXCELLENCE, CENTRALIZED SUPPORT Fertility care is local and deeply personal. We do not impose a single model on every practice — we preserve the reputation, physicians and patient relationships that made each clinic suecessful, and add th
Slide 14: Growth Strategy
Owvo tertility GROWTH STRATEGY FOUR PILLARS TO SCALE AND PROFITABILITY NASDAQ: IVF GROW THE CLINICS WE OWN + Increase patient volumes at each existing location + Broaden the service menu and add capacity + Expand payor access — Wisconsin joined Progyny + Telehealth to reach patients beyond the local
Slide 15: Technology: INVOcell and Expanding Access
ONVieriliry NASDAQ: IVF TECHNOLOGY INVOCELL AND THE CASE FOR EXPANDING ACCESS INVOcell® isa proprietary medical device — the first to allow fertilization and early embryo development to take place in vivo, within the woman's body, The IVC procedure it enables improves lab efficiency and capacity, re
Slide 16: Results and Financial Position
OInvoteriility RESULTS AND FINANCIAL POSITION FINANCIALS NASDAQ: IVF
Slide 17: Second Quarter 2026
Owvo tertility NASDAQ: IVF SECOND QUARTER 2026 REVENUE GROWTH AND CLINIC PROFITABILITY $2.2M +18% $333K $(1.0)M TOTAL REVENUE CLINIC REVENUE GROWTH CLINIC-LEVEL ADJ. EBITDA* ADJUSTED EBITDA* Up 17% from $1.9 in 02 2025 $2.17M compared with $1.83M Up from $164k in @1 2026; Company-wide, afterall $829
Slide 18: Financial Trajectory
Ovo Ferilty NASDAQ: IVF FINANCIAL TRAJECTORY REVENUE SCALE AND CLINIC EARNINGS POWER CONSOLIDATED REVENUE ($ MILLIONS) CLINIC-LEVEL ADJUSTED EBITDA ($ THOUSANDS)* ws 20 : a $1.76 $1.64 $1.58 sis s10 sos s00 22028 [post NAYAS=> [post NAYA=> 480 a bali $333 300 s24t $243 $164 $180 $89 80 |_| H 4 2025
Slide 19: The Investment Thesis
Owvo tertility NASDAQ: IVF THE INVESTMENT THESIS THE PATH TO CONSOLIDATED PROFITABILITY The clinic platform already earns money. The gap between a profitable clinic platform and a profitable company is a largely fixed corporate and public company cost base. Four levers close it GROW CLINIC EARNINGS.
Slide 20: Balance Sheet and Capitalization
Onvo: BALANCE SHEET AND CAPITALIZATION BALANCE SHEET HIGHLIGHTS FINANCIAL POSITION CAPITALIZATION NASDAQ: IVF TTS a TS Cash Total current assets, Goodwill Note receivable — NAYA Investmentin NAYA Total assets Total current liabilities Warrant lability Total liabilities Total stockholders’ equity 3,7
Slide 21: Leadership Team
Owvo tertility NASDAQ: IVF LEADERSHIP TEAM EXPERIENCED AND DEDICATED CORPORATE DOCTORS AND LAB DIRECTORS Steve Shum Terah Krigsvold Andrea Goren Sue Ellen Carpenter James Donahue Gretchen Collins Chief Executive Officer Chief Financial Officer M&A / Legal Bo Mitrovic April McGhee ‘Strategy / Busines
Slide 22: Board of Directors
Owvo tertility BOARD OF DIRECTORS INDEPENDENT AND ENGAGED @ @ ® Steve Shum Trent Davis Rebecca Messina Barbara Ryan CEO, Director Independent Director Independent Director Independent Director SELECTED PRIOR AFFILIATIONS _ ; BEAR enstsibe Cattle STEARNS wert maesco® Uber August 2028 ox NASDAQ: ‘Matt
Slide 23: Why Invest in INVO Fertility?
Ovo WHY INVEST IN INVO FERTILITY? KEY TAKEAWAYS NASDAQ: IVF FAVORABLE MARKET BACKDROP, + USS. IVF market estimated at $5.98 in 2025 + Estimated 4.5% CAGR through 2033 + Later family formation and expanding coverage ‘support demand + Capacity gaps remain in many secondary markets A PROFITABLE CLINIC
Slide 24: Thank You
mi) a THANK YOU For more information, please contact: Steve Shum, Chief Executive Officer 978-878-9505 x506 sshum@invofertlty.com invofertility.com SS RT.
Slide 25: Quarterly Statement of Operations
Ove APPENDIX QUARTERLY STATEMENT OF OPERATIONS (Sin thousands; unauetted) a CC Clinic revenue Productre Total revenue Cost of services and cost of goods sold Soling, general and administrative Impairmentloss Depreciation and amortization “Total operating expenses: Loss from operations Total otnerinc
Slide 26: Quarterly Balance Sheet Summary
Ovo Fersilty APPENDIX NASDAQ: QUARTERLY BALANCE SHEET SUMMARY (Sin thousands; unautes) LS ETS ETS CE cesh 2078 4908 ane “etal cient sete 278 S74 4009 Teil asets 020 24038 25035 uissismes ‘ecu pate ad aco aii 20a to 001 ‘eral conoueaion 200 ‘= 0 Ns py cret ton 178 128 saz ee ay, uit en 20 in 9 ‘ral p
Slide 27: Adjusted EBITDA Reconciliation
Ove ($ USD: unauatted) Net income (os) fom conning operations Interest expense and amortization of debt dlscount Interest income Income tax expense (bene) Depreciation and amortization Stockbased compensation adoption expense Non-cash compensation fr services Impairment ofinlangble assets Loss on de
Slide 28: Clinic-Level Adjusted EBITDA Reconciliation
OWvo ven NASDAQ: IVF APPENDIX CLINIC-LEVEL ADJUSTED EBITDA RECONCILIATION ($ USD; unaudited) Fertty Cinie Senoes revenue 4,921,589 1,932,004 s723.228 4,546,107 1,902,288 2,167,705 7417 428 Operating expenses 4,502,774 2,907,958 4,592,504 4,570,105 4,853,108 4,967 458 6,883,202 Segment prof (loss) 28
Slide 29: Capitalization: From Shares Outstanding to Fully Diluted
ONO fer CAPITALIZATION NASDAQ: IVF FROM SHARES OUTSTANDING TO FULLY DILUTED ‘As of June 30, 2026 PF execscicomenion rice] steel Warrants: Shares outstanding POTENTIAL DILUTION Warrants outstanding ‘Options outstanding Convertible notes and accrued interest Series 0 Preferred, as converted Total pote
Slide 30: Sources and Methodology
NASDAQ: IVF APPENDIX SOURCES AND METHODOLOGY ‘Third-party data referenced in this presentation, MARKET SIZE AND DEMAND 8 US IVF market of 8.88 in 2025 groving at a 4.5% CAGR through 2083 8 £35,426 ART cycles performed in 2022 across 487 reporting eins 8 Roughly 1 in people experience infty ‘OWNERSHI